#### **ENDOCRINE PRACTICE** Rapid Electronic Article in Press

Rapid Electronic Articles in Press are preprinted manuscripts that have been accepted for publication in an issue of Endocrine Practice. This version of the manuscript will be replaced with the final, paginated version after it has been published in Volume 21, Issue 4, April 2015 *Endocrine Practice*. DOI:10.4158/EP15693.CS © 2015 AACE.



# AACE/ACE COMPREHENSIVE DIABETES MANAGEMENT ALGORITHM ------2015


#### TASK FORCE

Alan J. Garber, MD, PhD, FACE, Chair

Martin J. Abrahamson, MD Joshua I. Barzilay, MD, FACE Lawrence Blonde, MD, FACP, FACE Zachary T. Bloomgarden, MD, MACE Michael A. Bush, MD Samuel Dagogo-Jack, MD, DM, FRCP, FACE Michael B. Davidson, DO, FACE Daniel Einhorn, MD, FACP, FACE Jeffrey R. Garber, MD, FACP, FACE W. Timothy Garvey, MD, FACE George Grunberger, MD, FACP, FACE Yehuda Handelsman, MD, FACP, FNLA, FACE Irl B. Hirsch, MD Paul S. Jellinger, MD, MACE Janet B. McGill, MD, FACE Jeffrey I. Mechanick, MD, FACP, FACE, FACN, ECNU Paul D. Rosenblit, MD, PhD, FNLA, FACE Guillermo Umpierrez, MD, FACP, FACE Michael H. Davidson, MD, *Advisor* 


COPYRIGHT © 2015 AACE MAY NOT BE REPRODUCED IN ANY FORM WITHOUT EXPRESS WRITTEN PERMISSION FROM AACE.

This material is protected by US copyright law. For permission to reused material in any format, complete a permission form at www.aace.com/permissions. To purchase reprints of this article, please visit: www.aace.com/reprints. DOI:10.4158/EP15693.CS Copyright © 2015 AACE.



### COMPLICATIONS-CENTRIC MODEL FOR CARE OF THE OVERWEIGHT/OBESE PATIENT








### PREDIABETES ALGORITHM

IFG (100-125) | IGT (140-199) | METABOLIC SYNDROME (NCEP 2005)









## INDIVIDUALIZE GOALS

# A1c ≤ 6.5%

For patients without concurrent serious illness and at low hypoglycemic risk


# A1c > 6.5%

For patients with concurrent serious illness and at risk for hypoglycemia




### GLYCEMIC CONTROL ALGORITHM

1993 ACCE ENDOCRINOLOGY




e6 AACE/ACE Comprehensive Diabetes Management Algorithm, Endocr Pract. 2015;21(No. 4)

### ALGORITHM FOR ADDING/INTENSIFYING INSULIN



COPYRIGHT © 2015 AACE MAY NOT BE REPRODUCED IN ANY FORM WITHOUT EXPRESS WRITTEN PERMISSION FROM AACE.

ACE





### PROFILES OF ANTIDIABETIC MEDICATIONS



	MET	GLP-1 RA	SGLT-2i	DPP-4i	AGi	TZD	SU GLN	COLSVL	BCR-QR	INSULIN	PRAML
НҮРО	Neutral	Neutral	Neutral	Neutral	Neutral	Neutral	Moderate/ Severe Mild	Neutral	Neutral	Moderate to Severe	Neutral
WEIGHT	Slight Loss	Loss	Loss	Neutral	Neutral	Gain	Gain	Neutral	Neutral	Gain	Loss
RENAL/ GU	Contra- indicated CKD Stage 3B,4,5	Exenatide Contra- indicated CrCl < 30	Genital Mycotic Infections	Dose Adjustment May be Necessary (Except Linagliptin)	Neutral	May Worsen Fluid Retention	More Hypo Risk	Neutral	Neutral	More Hypo Risk & Fluid Retention	Neutral
GI Sx	Moderate	Moderate	Neutral	Neutral	Moderate	Neutral	Neutral	Mild	Moderate	Neutral	Moderate
CHF	Neutral	Neutral	Neutral	Neutral	Neutral	Moderate	Neutral	Neutral	Neutral	Neutral	Neutral
CVD	Benefit		Increased LDL			Neutral	?		Safe		
BONE	Neutral	Neutral	Neutral	Neutral	Neutral	Moderate Bone Loss	Neutral	Neutral	Neutral	Neutral	Neutral

Few adverse events or possible benefits

Use with caution

Likelihood of adverse effects



### PRINCIPLES OF THE AACE ALGORITHM For the treatment of type 2 diabetes



- Lifestyle optimization and education are essential 1) for all patients with diabetes. Lifestyle modification designed for weight loss, including medical and surgical interventions approved for the treatment of obesity, should be considered as primary approaches for therapeutic benefits in overweight and obese patients with diabetes, and for prevention of diabetes in high risk patients with prediabetes. The treatment of overweight/obesity in patients with type 2 diabetes and prediabetes should proceed according to the Obesity Treatment Algorithm. Effective interventions for weight loss involve a multidisciplinary team. The need for medical therapy for weight loss or glycemic control should not be considered as a failure of lifestyle management, but as an adjunct to it.
- 2) The A1c target must be individualized, based on numerous factors, such as age, comorbid conditions, duration of diabetes, risk of hypoglycemia, patient motivation, adherence, life expectancy, etc. An A1c of 6.5% or less is still considered optimal if it can be achieved in a safe and affordable manner, but higher targets may be appropriate and may change in a given individual over time.
- 3) Minimizing risk of hypoglycemia is a priority. It is a matter of safety, adherence, and cost.
- 4) Minimizing risk of weight gain is a priority. It too is a matter of safety, adherence, and cost.
- 5) Glycemic control targets include fasting and postprandial glucose as determined by self blood glucose monitoring.
- 6) The choice of therapies must be individualized based on attributes of the patient (as above) and the medications themselves (see *Profiles of Antidiabetic Medications*). Attributes of medi-

cations that affect their choice include: risk of inducing hypoglycemia, risk of weight gain, ease of use, cost, and safety impact of kidney, heart, or liver disease. This algorithm includes every FDA-approved class of medications for diabetes. This algorithm also stratifies choice of therapies based on initial A1c.

- The algorithm provides guidance to what therapies to initiate and add, but respects individual circumstances that would make different choices.
- Therapies with complementary mechanisms of action must typically be used in combinations for optimum glycemic control.
- 9) Effectiveness of therapy must be evaluated frequently until stable (e.g. every 3 months) using multiple criteria including A1c, SMBG records including both fasting and post-prandial data, documented and suspected hypoglycemia, and monitoring for other potential adverse events (weight gain, fluid retention, hepatic, renal, or cardiac disease), and monitoring of comorbidities, relevant laboratory data, concomitant drug administration, diabetic complications, and psycho-social factors affecting patient care.
- 10) Safety and efficacy should be given higher priorities than initial acquisition cost of medications per se since cost of medications is only a small part of the total cost of care of diabetes. In determining the cost of a medication, consideration should be given to monitoring requirements, risk of hypoglycemia and weight gain, etc.
- The algorithm should be as simple as possible to gain physician acceptance and improve its utility and usability in clinical practice.
- 12) The algorithm should serve to help educate

the clinician as well as to guide therapy at the point of care.

- 13) The algorithm should conform, as nearly as possible, to a consensus for current standard of practice of care by expert endocrinologists who specialize in the management of patients with type 2 diabetes and have the broadest experience in outpatient clinical practice.
- 14) The algorithm should be as specific as possible, and provide guidance to the physician with prioritization and a rationale for selection of any particular regimen.
- 15) Rapid-acting insulin analogs are superior to Regular because they are more predictable.
- 16) Long-acting insulin analogs are superior to NPH insulin because they provide a fairly flat response for approximately 24 hours and provide better reproducibility and consistency both between subjects and within subjects, with a corresponding reduction in the risk of hypoglycemia.

This document represents the official position of the American Association of Clinical Endocrinologists and the American College of Endocrinology. Where there were no RCTs or specific FDA labeling for issues in clinical practice, the participating clinical experts utilized their judgment and experience. Every effort was made to achieve consensus among the committee members. Many details that could not be included in the graphic summary (Figure) are described in the text.

All necessary author disclosures are made to AACE and are on file at the main office. Please contact Lori Clawges at AACE for further inquiries.